Adrian Haigh Sells 22,222 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of the stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $9.91, for a total value of $220,220.02. Following the completion of the transaction, the chief operating officer now directly owns 22,222 shares in the company, valued at approximately $220,220.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Adrian Haigh also recently made the following trade(s):

• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.30, for a total value of $228,886.60.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at $9.34 on Friday. Fennec Pharmaceuticals Inc has a 1 year low of $6.30 and a 1 year high of $11.92. The business has a 50-day moving average of $10.09 and a two-hundred day moving average of $9.33. The company has a market capitalization of $253.11 million, a P/E ratio of -15.31 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). The business had revenue of $9.74 million during the quarter, compared to the consensus estimate of $9.47 million. On average, equities analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FENC has been the topic of several analyst reports. HC Wainwright increased their target price on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, April 4th. Craig Hallum increased their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Finally, Wedbush restated an “outperform” rating and issued a $16.00 price target on shares of Fennec Pharmaceuticals in a report on Monday, March 18th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. AIGH Capital Management LLC grew its holdings in shares of Fennec Pharmaceuticals by 6.9% during the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock worth $2,805,000 after buying an additional 24,069 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Fennec Pharmaceuticals during the third quarter worth about $50,000. Gendell Jeffrey L grew its holdings in shares of Fennec Pharmaceuticals by 0.9% during the third quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock worth $2,148,000 after buying an additional 2,579 shares in the last quarter. HRT Financial LP bought a new position in shares of Fennec Pharmaceuticals during the first quarter worth about $454,000. Finally, Citigroup Inc. grew its holdings in shares of Fennec Pharmaceuticals by 10.3% during the first quarter. Citigroup Inc. now owns 18,590 shares of the company’s stock worth $151,000 after buying an additional 1,742 shares in the last quarter. 55.51% of the stock is currently owned by institutional investors.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.